Anne Li September 16th, 2017 firstname.lastname@example.org
The drug fulvestrant (Faslodex) has not been recommended in England to treat late stage breast cancer, in draft guidance. The National Institute for Health and Care Excellence (NICE) has provisionally rejected fulvestrant for post-menopausal women with a form of the disease known as oestrogen-receptor positive. Professor Arnie Purushotham, Cancer Research UK’s senior clinical adviser, said that the decision was disappointing.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-09-01-breast-cancer-drug-not-recommended-for-use-in-england